Xencor, Inc. has extended its research collaboration with Roche to create monoclonal antibodies with differentiated pharmacological profiles. Roche and Xencor entered into an initial collaboration in January 2005, in which Roche would apply Xencor’s XmAb Fc domains with the aim of enhancing the therapeutic efficacy of an antibody against a cancer target. With this extension, Roche can further its research efforts against this target. “We are very pleased to continue working with...